PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34765016-0	2021	Shikonin regulates autophagy via the AMPK/mTOR pathway and reduces apoptosis of human umbilical cord mesenchymal stem cells to improve survival in tissues surrounding brain contusion.	shikonin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	42-46	
34765016-1	2021	Shikonin has been reported to regulate autophagy via the AMP-activated protein kinase (AMPK)/mTOR signalling pathway and decrease apoptosis in transplanted human umbilical cord mesenchymal stem cells (HUMSCs).	shikonin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	93-97	
34765016-3	2021	Differences in autophagy and AMPK/mTOR pathway-related protein expression following treatment with shikonin were quantitatively analyzed by western blotting.	shikonin	99-107	mechanistic target of rapamycin kinase	Homo sapiens	34-38	
34812264-0	2021	Shikonin Promotes Apoptosis and Attenuates Migration and Invasion of Human Esophageal Cancer Cells by Inhibiting Tumor Necrosis Factor Receptor-Associated Protein 1 Expression and AKT/mTOR Signaling Pathway.	shikonin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	184-188	
34812264-11	2021	More interestingly, we demonstrated that shRNA-TRAP1 played a synergistic role in shikonin-mediated regulation of protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling.	shikonin	82-90	mechanistic target of rapamycin kinase	Homo sapiens	137-166	
34812264-11	2021	More interestingly, we demonstrated that shRNA-TRAP1 played a synergistic role in shikonin-mediated regulation of protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling.	shikonin	82-90	mechanistic target of rapamycin kinase	Homo sapiens	168-172	
34812264-12	2021	Collectively, shikonin promoted apoptosis and attenuated migration and invasion of EC cells by inhibiting TRAP1 expression and AKT/mTOR signaling, indicating that shikonin may be a new drug for treating EC.	shikonin	14-22	mechanistic target of rapamycin kinase	Homo sapiens	131-135	
34812264-12	2021	Collectively, shikonin promoted apoptosis and attenuated migration and invasion of EC cells by inhibiting TRAP1 expression and AKT/mTOR signaling, indicating that shikonin may be a new drug for treating EC.	shikonin	163-171	mechanistic target of rapamycin kinase	Homo sapiens	131-135	
33334200-0	2021	Shikonin induces odontoblastic differentiation of dental pulp stem cells via AKT-mTOR signaling in the presence of CD44.	shikonin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	81-85	
33334200-6	2021	Shikonin-induced expression of DSPP was inhibited by PI3K, AKT, and mTOR inhibitors.	shikonin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	68-72	
33334200-8	2021	Conclusions: Shikonin can stimulate dental pulp stem cells to undergo odontoblastic differentiation through a mechanism involving the AKT-mTOR signaling pathway and CD44.	shikonin	13-21	mechanistic target of rapamycin kinase	Homo sapiens	138-142	
33334200-9	2021	Although expression of CD44 is important for inducing odontoblastic differentiation of dental pulp stem cells, the relationship between the AKT-mTOR signaling pathway and CD44 expression, in the context of shikonin stimulation, has not yet been elucidated.	shikonin	206-214	mechanistic target of rapamycin kinase	Homo sapiens	144-148	
29449346-0	2018	Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating miR-106b/PTEN/AKT/mTOR signaling pathway.	shikonin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	130-134	
35267423-0	2022	Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway.	shikonin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	133-137	
24905636-0	2014	Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways.	shikonin	0-8	mechanistic target of rapamycin kinase	Homo sapiens	112-116	
24905636-7	2014	In addition, shikonin significantly decreased the phosphorylation of AKT and mTOR in a dose-dependent manner while it induced extracellular signal-regulated kinase (ERK), p38 mitogen activated protein kinase (MAPK) and c-Jun N terminal kinase (JNK) phosphorylation.	shikonin	13-21	mechanistic target of rapamycin kinase	Homo sapiens	77-81	
24905636-10	2014	Together, shikonin inhibits aggressive prostate cancer cell migration and invasion by reducing MMP-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways and presents a potential novel alternative agent for the treatment of human prostate cancer.	shikonin	10-18	mechanistic target of rapamycin kinase	Homo sapiens	123-127